Melanotan II | High-Purity Hormone Research Peptide | USA Supplier

By Medical Team of Generic Peptides

In the 1980s, researchers at the University of Arizona had a simple, practical goal: design a synthetic version of the body's tanning hormone to reduce skin cancer by letting fair-skinned people tan without UV exposure. They built a modified version of alpha-melanocyte-stimulating hormone (α-MSH) — more stable, more potent — and called it Melanotan II.

Then, in 1993, one of the researchers testing the compound on himself did something that changed the peptide's history forever. He accidentally injected twice his intended dose. About eight hours later, instead of getting tanner, he got an erection that lasted eight hours.

This wasn't in anyone's protocol. The team had been looking for tanning effects. Nobody expected a hormone involved in skin pigmentation to also trigger massive sexual arousal. But it did — reproducibly, in both men and women. That accidental discovery launched a secondary research track that eventually produced PT-141 (bremelanotide), which was later FDA-approved for female sexual dysfunction.

Melanotan II itself never became a legitimate drug. It sits in regulatory limbo — unapproved anywhere, widely sold online, used by tens of thousands of people for tanning, libido, and appetite suppression. It has real effects, a genuinely interesting mechanism, and a safety profile that deserves more honesty than it usually gets.

Melanotan II: what it is and how it works in a nutshell

Melanotan II (MT-II) is a synthetic cyclic heptapeptide — seven amino acids in a ring structure — derived from α-MSH, the body's natural melanocyte-stimulating hormone. The cyclic structure and strategic modifications make it dramatically more potent and longer-acting than natural α-MSH.

It was developed at the University of Arizona by researchers Mac Hadley, Victor Hruby, and Norman Levine in the 1980s as a potential sunless tanning agent. The patent was licensed to Palatin Technologies, who discontinued direct development of MT-II in 2000 but kept working on its metabolite, bremelanotide (PT-141) — which the FDA eventually approved in 2019 for hypoactive sexual desire disorder in women.

Melanotan II itself was never approved for human use anywhere in the world. UK, Australian, and US health agencies have issued specific warnings against its use. Despite this, it's one of the most widely sold "gray market" peptides — purchased online, from gyms, and tanning salons, often marketed under names like "MT-2" or the "Barbie drug." [1]

Melanotan II mechanism of action: what it actually does in the body

Your body produces α-MSH as part of the pro-opiomelanocortin (POMC) system. This hormone acts on a family of five receptors — MC1R through MC5R — each doing different things. MT-II is a non-selective agonist that activates multiple members of this family simultaneously [2].

MC1R activation (tanning effect). Expressed on melanocytes in the skin. When stimulated, melanocytes produce more eumelanin (brown-black pigment) and less pheomelanin (yellow-red pigment). The result is deeper, more uniform skin pigmentation with genuine photoprotective properties — the darker pigment actually does absorb more UV radiation.

MC4R activation (appetite, sexual function). Expressed heavily in the hypothalamus. Activation:

• Suppresses appetite — MC4R is part of the body's master satiety signaling system
• Produces sexual arousal — erections in men, genital arousal and sexual desire in women, via central nervous system pathways (not a blood vessel effect like Viagra)
• Activates brown adipose tissue thermogenesis — influences energy expenditure

MC3R activation (energy balance). Contributes to metabolic effects, particularly in lipolysis and food intake regulation.

MC5R activation. Poorly characterized in humans but expressed in sebaceous glands and other tissues.

The Wessells 2000 human study in men with erectile dysfunction: subcutaneous MT-II produced penile erections in 17 of 20 subjects without sexual stimulation, with mean 41 minutes of rigidity greater than 80% on RigiScan monitoring. Increased sexual desire was reported in 68% of doses vs. 19% on placebo [3]. The effect isn't subtle.

Pharmacokinetics: MT-II's half-life is roughly 30 minutes, but biological effects persist much longer due to downstream melanogenic and neural signaling cascades. Tanning effects accumulate over weeks of dosing.

Who uses Melanotan II and what for

• Fair-skinned people wanting to tan — probably the largest user group. Particularly popular in northern Europe, UK, Australia, and Scandinavia where natural tanning is difficult.
• People seeking appetite suppression — either as primary goal or secondary benefit. The effect is meaningful in the first 2-4 weeks but often diminishes with continued use.
• Men and women seeking sexual enhancement — though PT-141 is more selective for this purpose and has actual regulatory approval for women.
• Bodybuilders for cosmetic contest prep — the deep, even tan that MT-II produces is genuinely hard to replicate with other methods.
• People with specific skin conditions like erythropoietic protoporphyria (EPP) — though the approved drug for this is Melanotan I (afamelanotide/Scenesse), not MT-II.

Realistic expectations over a 2-4 week loading phase: noticeable skin darkening within 5-7 days (much faster than natural tanning), significant appetite reduction in the first couple weeks, spontaneous erections (for men) that can be socially inconvenient, darker moles and freckles. Mature tan develops over 3-4 weeks of regular dosing.

What WON'T happen: a natural-looking tan for everyone (MT-II can produce uneven pigmentation, especially freckling), permanent tanning without maintenance doses, any FDA-approved legitimacy, protection from skin cancer that offsets the risks we'll discuss below.

What Melanotan II stacks with: popular combinations

Unlike peptides in the GH or fertility category, MT-II isn't typically stacked. It's usually used alone for its specific effects. Occasional combinations:

• MT-II + PT-141 (bremelanotide) — not a combination that makes pharmacological sense (they're structurally related and hit overlapping receptors), but occasionally used by people looking to amplify sexual effects while developing a tan.
• MT-II + AOD-9604 or HGH Fragment 176-191 — some people pair MT-II with fat-loss peptides, given MT-II's appetite suppression adds to the overall body composition effect.

Generally avoided when: using any other MC4R agonist (redundant and unpredictable), during pregnancy or breastfeeding (no safety data), if any skin lesions are changing.

Melanotan II side effects and risks

This is the section that matters most with this peptide. The side effect profile is genuinely significant, and the long-term safety data is essentially absent because MT-II has never been through full clinical trials.

Common acute side effects:

• Nausea — very common, especially during loading phase. Can be severe at higher doses. In the Wessells study, 12.9% of subjects had severe nausea at 0.025 mg/kg [3].
• Facial flushing — within minutes of injection, common, transient.
• Yawning — described as "excessive yawning," sometimes compulsive. Mechanism not fully understood but reproducible.
• Spontaneous erections — in men, especially during loading phase. Can occur at inconvenient times.
• Appetite suppression — can be severe enough to cause problematic undereating.

Skin-related concerns:

• Darkening and enlargement of existing moles — this is the one that keeps dermatologists up at night. MT-II stimulates melanocyte proliferation, and atypical nevi may darken or change appearance. Monitoring existing moles during and after MT-II use is essential.
• New mole formation — reported in multiple case reports.
• Uneven pigmentation — particularly freckling or "dirty looking" tanning in some users.
• Skin changes including lentigines — darker pigmented spots.

The melanoma question. Multiple case reports have documented melanoma diagnoses in MT-II users. A 2013 scientific review found no conclusive evidence that MT-II causes melanoma [4]. A 2021 review concluded that increased melanoma risk in users "can probably be explained by more UV exposure" (because MT-II users often also pursue additional tanning) [1]. The truth likely sits in the middle: MT-II doesn't obviously cause melanoma, but melanocyte stimulation combined with UV-seeking behavior is not a reassuring combination, and we don't have long-term trial data to rule out direct effects.

Who should absolutely avoid:

• Anyone with history of melanoma or atypical nevi
• Anyone with many moles, changing moles, or dysplastic nevus syndrome
• Pregnant or breastfeeding women
• People with cardiovascular disease (MT-II has cardiovascular effects that aren't well-characterized long-term)
• People with active skin cancer or suspicious skin lesions
• Competitive athletes — while MT-II isn't specifically on the WADA prohibited list, related compounds are under scrutiny and contamination is a real concern.

How to use and store Melanotan II

Subcutaneous injection. Oral bioavailability is essentially zero.

Typical protocols:

• Loading phase: start very low (125-250 mcg) and increase gradually to 500 mcg-1 mg daily over 7-10 days
• Maintenance phase: 500-1000 mcg once or twice weekly to maintain tan
• Cycle length: not a true "cycle" peptide — most users do 2-3 week loading, then indefinite low-dose maintenance during desired tan periods
• Timing: evening dosing is common because of the nausea and drowsiness it can cause. Also, MT-II combined with some UV exposure (sun or sunbed) produces faster tanning results — though this is where the risk profile gets worse.

Critical dosing caveat: start lower than you think. The side effects (nausea especially) are dose-dependent and can be brutal at higher doses. Many experienced users stay below 500 mcg per injection permanently.

Storage: lyophilized powder in freezer at -20°C. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 30 days.

Melanotan II vs alternatives: what's different

• Melanotan I (afamelanotide / Scenesse) — FDA-approved, selective for MC1R, tanning effect without the appetite and sexual side effects. Expensive, requires prescription, implanted rather than injected. The "clean" version of MT-II.
• PT-141 (bremelanotide) — selective MC4R agonist developed from MT-II. FDA-approved for female HSDD. For sexual effects specifically, this is the legitimate medical option.
• Sunless tanning lotions (DHA-based) — surface-level, no receptor effects, no systemic risks. Different approach entirely, no real UV protection.
• UV tanning beds — direct skin damage. Generally considered higher risk than MT-II combined with natural sun, but this comparison varies by individual.

MT-II's distinguishing feature: the only peptide that produces genuine melanogenesis at the molecular level, affecting appetite, sexual function, and skin tanning in a single compound. This is both why it's useful and why it has a complicated risk profile — you can't activate the melanocortin system without hitting all of it.

Myths about Melanotan II

• "Melanotan II prevents skin cancer." Partial truth that gets stretched. Eumelanin produced by MT-II does offer some UV absorption, which in theory reduces UV damage. But users typically combine MT-II with increased sun exposure to "make the tan show up" — which negates the protective effect. MT-II also stimulates melanocyte proliferation, which is at least theoretically concerning for atypical mole development. Calling it a "skin cancer prevention drug" overstates what's actually supported.
• "If PT-141 got FDA approved, Melanotan II must be safe too." PT-141 is selective for MC4R and doesn't stimulate melanocytes systemically. MT-II is non-selective and hits MC1R, MC4R, and others. The approval of PT-141 tells you something about the safety of selective MC4R stimulation, not about broad melanocortin agonism.

Sources

1. Habbema, L., Halk, A. B., Neumann, M., & Bergman, W. (2013). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 52(5), 523-531. — comprehensive review of safety concerns with unregulated MT-II use.
2. Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. — foundational review by one of MT-II's original developers covering the peptide's full history.
3. Wessells, H., Levine, N., Hadley, M. E., Dorr, R., & Hruby, V. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 12(Suppl 4), S74-S79. https://www.nature.com/articles/3900582 — the landmark clinical study documenting erectile and sexual motivation effects in men with ED.
4. Langan, E. A., Nie, Z., & Rhodes, L. E. (2010). Melanotropic peptides: more than just "Barbie drugs" and "sun-tan jabs"? British Journal of Dermatology, 163(3), 451-455. — clinical perspective on the medical landscape around MT-II.
5. Diamanti-Kandarakis, E., Besser, G. M., & Grossman, A. (2005). Discovery that a melanocortin regulates sexual functions in male and female humans. Proceedings of the National Academy of Sciences, 102(24), 8572-8577. https://pubmed.ncbi.nlm.nih.gov/15996790/ — key paper establishing melanocortin's role in sexual function.
6. Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784. — early pharmacology work on MT-II in humans.
7. Clinuvel Pharmaceuticals / Scenesse (afamelanotide) FDA approval information. — context on the related, approved Melanotan I compound.

Melanotan II Dosage Guide

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds non-selectively across melanocortin receptors MC1R, MC3R, MC4R, and MC5R, producing chemically-induced tanning along with secondary effects on appetite and sexual arousal. This guide is aimed at fair-skinned users who tan poorly under UV alone, those seeking a faster or darker tan with minimal sun exposure, and users exploring MT-II's documented effects on libido and appetite suppression. Dosing below combines the Dorr et al. 1996 Phase I pilot study (0.025 mg/kg/day), the Wessells erectile dysfunction trials, and community loading/maintenance protocols refined over two decades of underground use.

Real-World Dosage Protocols by Experience Level

Doses also shift depending on the specific goal. The same peptide used for tanning versus appetite or libido support can follow quite different protocols.

Dosage by Goal

Inject in the evening with food and on an empty stomach is not required — nausea is the single most common deterrent (affecting 80–90% of users during loading), and bedtime dosing lets you sleep through the worst of it while an antiemetic like ondansetron or ginger helps the first 3–5 doses. Do not skip the skin check before starting; MT-II stimulates all melanocytes and causes documented mole darkening, new naevi, and atypical naevus changes, so a baseline dermatological evaluation and ongoing mole monitoring are non-negotiable. Absolute contraindications include personal or family history of melanoma, atypical mole syndrome (>50 moles), Fitzpatrick skin type VI (no benefit), active cancer, uncontrolled hypertension, severe cardiovascular disease, and pregnancy — rhabdomyolysis and priapism have been reported at higher doses.

Melanotan II Storage Guide: How to Keep Your Research Peptide Stable and Effective

Melanotan II ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its cyclic heptapeptide structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.

Lyophilized Powder (Unreconstituted)

Shipping & Product Authenticity

Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.

Shipping Times

Direct Supply & Secure Delivery

This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.

Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.

What to Expect

• Orders are processed after payment confirmation
• USA domestic shipping is typically faster when local stock is selected
• International orders include tracking, though update frequency may vary by destination
• Multiple warehouses may result in separate shipments when applicable

Authenticity & Verified Supply

Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.

Shipping & Returns